2016
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, Brass LM, Schwartz GG, Adams HP, Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O'Leary JR, Parsons MW, Ringleb P, Sen S, Spence JD, Tanne D, Wang D, Winder TR. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. New England Journal Of Medicine 2016, 374: 1321-1331. PMID: 26886418, PMCID: PMC4887756, DOI: 10.1056/nejmoa1506930.Peer-Reviewed Original ResearchConceptsTransient ischemic attackIschemic strokeInsulin resistanceMyocardial infarctionIschemic attackPrimary outcomeRecent ischemic strokeDouble-blind trialFuture cardiovascular eventsHomeostasis model assessmentInsulin resistance indexRisk of strokeEligible patientsNonfatal strokePioglitazone groupCardiovascular eventsCause mortalityPlacebo groupPreventive therapyCerebrovascular diseaseInsulin sensitivityRisk factorsResistance indexHigh riskLower risk
2001
A Clinical Trial of Estrogen-Replacement Therapy after Ischemic Stroke
Viscoli C, Brass L, Kernan W, Sarrel P, Suissa S, Horwitz R. A Clinical Trial of Estrogen-Replacement Therapy after Ischemic Stroke. New England Journal Of Medicine 2001, 345: 1243-1249. PMID: 11680444, DOI: 10.1056/nejmoa010534.Peer-Reviewed Original ResearchConceptsEstrogen replacement therapyEstrogen therapyNonfatal strokePostmenopausal womenIschemic strokeCerebrovascular diseasePlacebo-controlled trialTransient ischemic attackOccurrence of strokeRisk of deathIschemic attackFatal strokeMean followPlacebo groupSecondary preventionEstradiol groupFunctional deficitsClinical trialsObservational studyHigh riskWoman's riskTherapyStrokeWomenDeath